# Peptides Studied for Fatty Liver Disease (MASH): The Trials

Source: https://pepvault.app/conditions/fatty-liver-disease

Last updated: 2026-11-19

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Research](https://pepvault.app/research) [By condition](https://pepvault.app/conditions) Fatty Liver Disease (MASH)

Peptides by condition · Weight, blood sugar, liver and gut

# Peptides studied for fatty liver disease (MASH)

Checked November 2026 against our study pages and the FDA labels [Published by PepVault](https://pepvault.app/guides/how-we-research)

Our library holds 15 study pages on fatty liver disease (MASH): 12 in people (all meta-analyses or randomized trials), and 3 in animals. They studied 8 compounds, with this many study pages each: Pemvidutide 4, Efinopegdutide 2, Tesamorelin 2, Semaglutide 1, Survodutide 1, Tirzepatide 1, Retatrutide 3 and HGH 1.

## What the research on fatty liver disease (MASH) looks like

Fatty liver disease is fat building up in the liver, often alongside excess weight and type 2 diabetes. Its medical names have changed: MASLD is the fat itself, and MASH, once called NASH, is the form with inflammation that can scar the liver over time. The newer drugs that act on GLP-1 and glucagon have reached trials here.

These trials measure liver fat on an MRI scan, or take a small piece of liver (a biopsy) to see whether the inflammation cleared and whether scarring, called fibrosis, got worse. Clearing the inflammation without worse scarring is the result regulators look for.

A drop in liver fat on a scan is an early sign; a biopsy result after a year or more is stronger. Mouse models of fatty liver are built in different ways, so a result in one may not carry over to another, let alone to people.

How many of the 15 study pages on this condition reach each design, strongest at the top: meta-analyses and randomized trials in people, other studies in people, animals, cells.

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Track your own progress in PepVault

Doses, vials, weight and side effects in one log.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=conditions-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## The 15 studies, by compound

Grouped by the compound each study is filed under, and within each, strongest design first. Each line gives the design, who was studied, how many and the year, before the finding.

1. ### [Pemvidutide](https://pepvault.app/peptides/pemvidutide)

   3 in people · 1 in animals

   For fatty liver disease (MASH), 4 of our study pages are filed under Pemvidutide: 3 randomized trials in people, and 1 animal study (mice). The largest in people enrolled 212 people and was published in 2026. They were published from 2022 to 2026, in Lancet Gastroenterol Hepatol, Lancet, JHEP Rep and Sci Rep.

   Pemvidutide has no FDA-approved product: Drugs@FDA lists no application for it.

   - Randomized trial in people · 212 people · 2026 [Pemvidutide: liver fat down 54.7% at 48 weeks in IMPACT MASH trial](https://pepvault.app/research/pemvidutide-impact-2026)
   - Randomized trial in people · 212 people · 2025 [Pemvidutide: MASH resolved in up to 58% vs 20% on placebo at 24 weeks](https://pepvault.app/research/pemvidutide-impact-2025)
   - Randomized trial in people · 64 people · 2025 [Pemvidutide: up to 76.4% liver fat reduction at 24 weeks in MASLD](https://pepvault.app/research/pemvidutide-browne-2025)
   - Animal study in mice · 2022 [Pemvidutide cut body weight about 25% in mice with NASH](https://pepvault.app/research/pemvidutide-nestor-2022)

   - [Pemvidutide: legal and regulatory status](https://pepvault.app/peptides/pemvidutide/legal-status)
   - [Pemvidutide in the library](https://pepvault.app/peptides/pemvidutide)
   - [Pemvidutide dose guide](https://pepvault.app/lab/dosage/pemvidutide)
2. ### [Efinopegdutide](https://pepvault.app/peptides/efinopegdutide)

   2 in people

   For fatty liver disease (MASH), 2 of our study pages are filed under Efinopegdutide: 2 randomized trials in people. The largest in people enrolled 381 people and was published in 2026. They were published from 2023 to 2026, in Lancet and J Hepatol.

   Efinopegdutide has no FDA-approved product: Drugs@FDA lists no application for it.

   - Randomized trial in people · 381 people · 2026 [Efinopegdutide: MASH resolved in up to 63% vs 13% on placebo](https://pepvault.app/research/efinopegdutide-lawitz-2026)
   - Randomized trial in people · 145 people · 2023 [Efinopegdutide: 72.7% liver fat drop vs 42.3% on semaglutide](https://pepvault.app/research/efinopegdutide-romero-gomez-2023)

   - [Efinopegdutide: legal and regulatory status](https://pepvault.app/peptides/efinopegdutide/legal-status)
   - [Efinopegdutide in the library](https://pepvault.app/peptides/efinopegdutide)
   - [Efinopegdutide dose guide](https://pepvault.app/lab/dosage/efinopegdutide)
3. ### [Tesamorelin](https://pepvault.app/peptides/tesamorelin)

   2 in people

   For fatty liver disease (MASH), 2 of our study pages are filed under Tesamorelin: 2 randomized trials in people. The largest in people enrolled 50 people and was published in 2014. They were published from 2014 to 2020, in JAMA and JCI Insight.

   FDA-approved for other uses, not for fatty liver disease (MASH): Egrifta (injection) for reducing excess belly fat in adults with HIV and lipodystrophy (its label says it is not for weight loss).

   - Randomized trial in people · 50 people · 2014 [Tesamorelin cut visceral and liver fat over 6 months in HIV patients](https://pepvault.app/research/tesamorelin-stanley-2014)
   - Randomized trial in people · 2020 [Tesamorelin shifted liver gene activity in HIV-related fatty liver](https://pepvault.app/research/tesamorelin-fourman-2020)

   - [Tesamorelin: legal and regulatory status](https://pepvault.app/peptides/tesamorelin/legal-status)
   - [Tesamorelin in the library](https://pepvault.app/peptides/tesamorelin)
   - [Tesamorelin dose guide](https://pepvault.app/lab/dosage/tesamorelin)
4. ### [Semaglutide](https://pepvault.app/peptides/semaglutide)

   1 in people

   For fatty liver disease (MASH), 1 of our study pages is filed under Semaglutide: 1 randomized trial in people. It enrolled 1,197 people and was published in 2025, in N Engl J Med.

   FDA-approved, with a use tied to fatty liver disease (MASH) on its label: Wegovy (injection) for weight loss and keeping it off, lowering heart risk in adults with heart disease and excess weight, and a fatty-liver disease (MASH) with moderate to advanced scarring; Wegovy (tablet) for weight loss and keeping it off, and lowering heart risk in adults with heart disease and excess weight. Under Ozempic and Rybelsus it is approved for other uses.

   - Randomized trial in people · 1,197 people · 2025 [Semaglutide: MASH resolved in 62.9% vs 34.3% on placebo at 72 weeks](https://pepvault.app/research/semaglutide-sanyal-2025)

   - [Wegovy, from its FDA label](https://pepvault.app/drugs/wegovy)
   - [Semaglutide: legal and regulatory status](https://pepvault.app/peptides/semaglutide/legal-status)
   - [Semaglutide in the library](https://pepvault.app/peptides/semaglutide)
   - [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)
5. ### [Survodutide](https://pepvault.app/peptides/survodutide)

   1 in people

   For fatty liver disease (MASH), 1 of our study pages is filed under Survodutide: 1 randomized trial in people. It enrolled 216 people and was published in 2026, in Nat Med.

   Survodutide has no FDA-approved product: Drugs@FDA lists no application for it. FDA writes that it has warned companies that illegally sold unapproved drugs containing survodutide, among others, labeled “for research purposes”.

   - Randomized trial in people · 216 people · 2026 [Survodutide: 12.2% weight loss and less liver fat at 48 weeks](https://pepvault.app/research/survodutide-synchronize-masld-2026)

   - [Survodutide: legal and regulatory status](https://pepvault.app/peptides/survodutide/legal-status)
   - [Survodutide in the library](https://pepvault.app/peptides/survodutide)
   - [Survodutide dose guide](https://pepvault.app/lab/dosage/survodutide)
6. ### [Tirzepatide](https://pepvault.app/peptides/tirzepatide)

   1 in people

   For fatty liver disease (MASH), 1 of our study pages is filed under Tirzepatide: 1 randomized trial in people. It enrolled 190 people and was published in 2024, in N Engl J Med.

   FDA-approved for other uses, not for fatty liver disease (MASH): Mounjaro (injection) for blood sugar control in type 2 diabetes (adults and children 10 and older), and lowering heart risk in adults with type 2 diabetes; Zepbound (injection) for weight loss and keeping it off, and moderate to severe obstructive sleep apnea in adults with obesity.

   - Randomized trial in people · 190 people · 2024 [Tirzepatide: 62% MASH resolution in 15 mg arm vs 10% on placebo](https://pepvault.app/research/tirzepatide-synergy-nash-2024)

   - [Tirzepatide: legal and regulatory status](https://pepvault.app/peptides/tirzepatide/legal-status)
   - [Tirzepatide in the library](https://pepvault.app/peptides/tirzepatide)
   - [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)
7. ### [Retatrutide](https://pepvault.app/peptides/retatrutide)

   1 in people · 2 in animals

   For fatty liver disease (MASH), 3 of our study pages are filed under Retatrutide: 1 randomized trial in people, and 2 animal studies (mice and hamsters). The largest in people enrolled 98 people and was published in 2024. They were published from 2024 to 2026, in Nat Med, Obesity (Silver Spring) and Am J Physiol Gastrointest Liver Physiol.

   Retatrutide has no FDA-approved product: Drugs@FDA lists no application for it, and FDA writes that it is not a component of any FDA-approved drug.

   - Randomized trial in people · 98 people · 2024 [Retatrutide: up to 82.4% less liver fat at 24 weeks in MASLD trial](https://pepvault.app/research/retatrutide-sanyal-2024)
   - Animal study in mice and hamsters · 2026 [Retatrutide cut body weight by 31% in obese mice with MASH](https://pepvault.app/research/retatrutide-briand-2026)
   - Animal study in mice · 2025 [Retatrutide eased diet-induced steatohepatitis in female mice](https://pepvault.app/research/retatrutide-viebahn-2025)

   - [Retatrutide: legal and regulatory status](https://pepvault.app/peptides/retatrutide/legal-status)
   - [Retatrutide in the library](https://pepvault.app/peptides/retatrutide)
   - [Retatrutide dose guide](https://pepvault.app/lab/dosage/retatrutide)
8. ### [HGH](https://pepvault.app/peptides/hgh)

   1 in people

   For fatty liver disease (MASH), 1 of our study pages is filed under HGH: 1 randomized trial in people. It enrolled 24 people and was published in 2021, in Clin Endocrinol (Oxf).

   FDA-approved for other uses, not for fatty liver disease (MASH): Humatrope (injection) for growth failure in children who make too little growth hormone and several other causes of short stature, and growth hormone deficiency in adults.

   - Randomized trial in people · 24 people · 2021 [HGH: liver fat 3.3% lower at 24 weeks vs no treatment, not significant](https://pepvault.app/research/hgh-pan-2021)

   - [HGH: legal and regulatory status](https://pepvault.app/peptides/hgh/legal-status)
   - [HGH in the library](https://pepvault.app/peptides/hgh)
   - [HGH dose guide](https://pepvault.app/lab/dosage/hgh)

## On fatty liver disease (MASH)

### Pemvidutide

- [Pemvidutide: the full reference](https://pepvault.app/peptides/pemvidutide)
- [Pemvidutide dose guide](https://pepvault.app/lab/dosage/pemvidutide)

### Efinopegdutide

- [Efinopegdutide: the full reference](https://pepvault.app/peptides/efinopegdutide)
- [Efinopegdutide dose guide](https://pepvault.app/lab/dosage/efinopegdutide)

### Mixing charts

- [Pemvidutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/pemvidutide-10mg)
- [Efinopegdutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/efinopegdutide-10mg)
- [Tesamorelin 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/tesamorelin-2mg)
- [Tesamorelin 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tesamorelin-10mg)
- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)

### Studies

- [Pemvidutide: liver fat down 54.7% at 48 weeks in IMPACT MASH trial](https://pepvault.app/research/pemvidutide-impact-2026)
- [Pemvidutide: up to 76.4% liver fat reduction at 24 weeks in MASLD](https://pepvault.app/research/pemvidutide-browne-2025)
- [Pemvidutide: MASH resolved in up to 58% vs 20% on placebo at 24 weeks](https://pepvault.app/research/pemvidutide-impact-2025)
- [All 4 studies](https://pepvault.app/research#pemvidutide)
- [Efinopegdutide: MASH resolved in up to 63% vs 13% on placebo](https://pepvault.app/research/efinopegdutide-lawitz-2026)
- [Efinopegdutide: 72.7% liver fat drop vs 42.3% on semaglutide](https://pepvault.app/research/efinopegdutide-romero-gomez-2023)
- [Efinopegdutide: up to 7.2% more weight loss than placebo at 12 weeks](https://pepvault.app/research/efinopegdutide-di-prospero-2021)
- [All 3 studies](https://pepvault.app/research#efinopegdutide)

### Compared with

- [Pemvidutide vs Efinopegdutide](https://pepvault.app/peptides/compare/pemvidutide-vs-efinopegdutide)
- [Semaglutide vs Efinopegdutide](https://pepvault.app/peptides/compare/semaglutide-vs-efinopegdutide)
- [Survodutide vs Efinopegdutide](https://pepvault.app/peptides/compare/survodutide-vs-efinopegdutide)
- [Sermorelin vs Tesamorelin](https://pepvault.app/peptides/compare/sermorelin-vs-tesamorelin)
- [Ipamorelin vs Tesamorelin](https://pepvault.app/peptides/compare/ipamorelin-vs-tesamorelin)
- [HGH vs Tesamorelin](https://pepvault.app/peptides/compare/hgh-vs-tesamorelin)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### Related conditions

- [Peptides studied for obesity](https://pepvault.app/conditions/obesity)
- [Peptides studied for HIV lipodystrophy](https://pepvault.app/conditions/hiv-lipodystrophy)
- [Peptides studied for type 2 diabetes](https://pepvault.app/conditions/type-2-diabetes)
- [Peptides studied for obstructive sleep apnea](https://pepvault.app/conditions/sleep-apnea)

### By goal

- [Peptides for weight loss](https://pepvault.app/peptides/for/weight-loss)
- [Peptides for muscle growth](https://pepvault.app/peptides/for/muscle-growth)

### Terms on this page

- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Glucagon](https://pepvault.app/glossary/glucagon)
- [MASH](https://pepvault.app/glossary/mash)

## Side by side

For the 8 compounds on this page: studies in people, studies in animals or cells, the size of the largest study in people, and the FDA status from the labels our status pages read (a dash where they hold no record).

| Compound | In people | Animals or cells | Largest in people | FDA |
| --- | --- | --- | --- | --- |
| [Pemvidutide](https://pepvault.app/peptides/pemvidutide) | 3 | 1 | 212 | Not approved |
| [Efinopegdutide](https://pepvault.app/peptides/efinopegdutide) | 2 | 0 | 381 | Not approved |
| [Tesamorelin](https://pepvault.app/peptides/tesamorelin) | 2 | 0 | 50 | Approved for other uses |
| [Semaglutide](https://pepvault.app/peptides/semaglutide) | 1 | 0 | 1,197 | Approved, a use tied to it |
| [Survodutide](https://pepvault.app/peptides/survodutide) | 1 | 0 | 216 | Not approved |
| [Tirzepatide](https://pepvault.app/peptides/tirzepatide) | 1 | 0 | 190 | Approved for other uses |
| [Retatrutide](https://pepvault.app/peptides/retatrutide) | 1 | 2 | 98 | Not approved |
| [HGH](https://pepvault.app/peptides/hgh) | 1 | 0 | 24 | Approved for other uses |

## What the studies did not show

Each study page names its own limits. These are the questions still open, in the study pages’ words.

- [Pemvidutide: liver fat down 54.7% at 48 weeks in IMPACT MASH trial](https://pepvault.app/research/pemvidutide-impact-2026) No liver biopsies were taken at week 48, so these results rest on non-invasive tests and are secondary endpoints, not the trial's main biopsy-based goals, which were measured at week 24. It was a mid-size phase 2b trial funded by Altimmune.
- [Efinopegdutide: MASH resolved in up to 63% vs 13% on placebo](https://pepvault.app/research/efinopegdutide-lawitz-2026) This was a mid-stage trial that lasted 1 year. It does not show longer-term liver outcomes. The semaglutide arm was open-label, and the trial was funded by Merck Sharp & Dohme.
- [Tesamorelin cut visceral and liver fat over 6 months in HIV patients](https://pepvault.app/research/tesamorelin-stanley-2014) This was a small, preliminary trial at a single center that lasted 6 months, and it only included people with HIV and extra abdominal fat. It does not show whether the fat changes matter for health or what happens over the long term.
- [Semaglutide: MASH resolved in 62.9% vs 34.3% on placebo at 72 weeks](https://pepvault.app/research/semaglutide-sanyal-2025) These are 72-week interim results from the first 800 patients in a trial still running toward 240 weeks, so longer-term outcomes are not yet known. The trial was funded by Novo Nordisk.
- [Survodutide: 12.2% weight loss and less liver fat at 48 weeks](https://pepvault.app/research/survodutide-synchronize-masld-2026) The trial lasted only 48 weeks and enrolled people only in the United States and Spain. It tested a single dose, 6.0 mg, against placebo.
- [Tirzepatide: 62% MASH resolution in 15 mg arm vs 10% on placebo](https://pepvault.app/research/tirzepatide-synergy-nash-2024) This was a 52-week phase 2 trial, and only 157 of the 190 people had a week 52 liver biopsy that could be scored, so missing results were filled in using the placebo group's pattern. It was funded by Eli Lilly, and the authors say larger and longer trials are needed.
- [Retatrutide: up to 82.4% less liver fat at 24 weeks in MASLD trial](https://pepvault.app/research/retatrutide-sanyal-2024) This is a substudy of a larger obesity trial with 98 people, and its main result comes at 24 weeks. It measured liver fat, not longer-term liver health outcomes.

This page is a reading of published studies, not medical advice. A diagnosis, and what to do about it, is a conversation with a clinician.

## Related pages

- [Peptides studied for obesity 1 study in common](https://pepvault.app/conditions/obesity)
- [Peptides studied for HIV lipodystrophy 1 study in common](https://pepvault.app/conditions/hiv-lipodystrophy)
- [Peptides studied for type 2 diabetes 5 compounds in common](https://pepvault.app/conditions/type-2-diabetes)
- [Peptides studied for obstructive sleep apnea 2 compounds in common](https://pepvault.app/conditions/sleep-apnea)

### By goal

- [Peptides for weight loss](https://pepvault.app/peptides/for/weight-loss)
- [Peptides for muscle growth](https://pepvault.app/peptides/for/muscle-growth)

### Trial terms

- [Randomized controlled trial (RCT)](https://pepvault.app/glossary/randomized-controlled-trial)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Phase 1, 2 and 3 trials](https://pepvault.app/glossary/clinical-trial-phases)
- [Meta-analysis](https://pepvault.app/glossary/meta-analysis)
- [In vivo](https://pepvault.app/glossary/in-vivo)

## Questions

### Which peptides have been studied for fatty liver disease (MASH)?

Our 15 study pages on fatty liver disease (MASH) are filed under 8 compounds, with this many each: Pemvidutide 4, Efinopegdutide 2, Tesamorelin 2, Semaglutide 1, Survodutide 1, Tirzepatide 1, Retatrutide 3 and HGH 1. Pemvidutide has the most.

### Have any been tested in people with fatty liver disease (MASH)?

Yes: 12 of the 15 were in people, all of them meta-analyses or randomized trials (Pemvidutide, Efinopegdutide, Tesamorelin, Semaglutide, Survodutide, Tirzepatide, Retatrutide and HGH). The largest enrolled 1,197 people: “Semaglutide: MASH resolved in 62.9% vs 34.3% on placebo at 72 weeks” (2025).

### Is any peptide FDA-approved for fatty liver disease (MASH)?

Yes, with a use tied to fatty liver disease (MASH) on their FDA labels: Semaglutide as Wegovy. 7 other compounds here with an FDA record have no use tied to it.

### How large were the studies in people on fatty liver disease (MASH)?

Of the 12 in people, 11 give their size on our pages: 1 had 1,000 people or more, 6 had 100 to 999 and 4 had fewer than 100. The largest, a randomized trial from 2025, enrolled 1,197.

### What did the animal and cell studies on fatty liver disease (MASH) use?

3 animal studies (mice and hamsters), filed under Retatrutide and Pemvidutide. A result in animals or cells shows what to test next, not what happens in a person.

### What is the newest study on fatty liver disease (MASH) here?

Of our study pages on fatty liver disease (MASH), the newest is “Efinopegdutide: MASH resolved in up to 63% vs 13% on placebo”, a randomized trial in people published in 2026.

## How this page was built

A study page is listed here only where we read its question, design and finding and the study was about this condition: its subjects had the condition, or were an animal or cell model of it, and the study gave them the compound. A study that only mentions the condition is not listed.

Studies are grouped by the compound each is filed under and ordered by design: meta-analyses and randomized trials in people first, then other studies in people, then animals, then cells, and within a group by size and then by year. The FDA status comes from the labels our legal-status and brand pages read.

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=conditions-card-next&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Track your own progress in PepVault

Doses, vials, weight and side effects in one log.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=conditions-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Track your own progress in PepVault

Doses, vials, weight and side effects in one log.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=conditions-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## On fatty liver disease (MASH)

### Pemvidutide

- [Pemvidutide: the full reference](https://pepvault.app/peptides/pemvidutide)
- [Pemvidutide dose guide](https://pepvault.app/lab/dosage/pemvidutide)

### Efinopegdutide

- [Efinopegdutide: the full reference](https://pepvault.app/peptides/efinopegdutide)
- [Efinopegdutide dose guide](https://pepvault.app/lab/dosage/efinopegdutide)

### Mixing charts

- [Pemvidutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/pemvidutide-10mg)
- [Efinopegdutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/efinopegdutide-10mg)
- [Tesamorelin 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/tesamorelin-2mg)
- [Tesamorelin 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tesamorelin-10mg)
- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)

### Studies

- [Pemvidutide: liver fat down 54.7% at 48 weeks in IMPACT MASH trial](https://pepvault.app/research/pemvidutide-impact-2026)
- [Pemvidutide: up to 76.4% liver fat reduction at 24 weeks in MASLD](https://pepvault.app/research/pemvidutide-browne-2025)
- [Pemvidutide: MASH resolved in up to 58% vs 20% on placebo at 24 weeks](https://pepvault.app/research/pemvidutide-impact-2025)
- [All 4 studies](https://pepvault.app/research#pemvidutide)
- [Efinopegdutide: MASH resolved in up to 63% vs 13% on placebo](https://pepvault.app/research/efinopegdutide-lawitz-2026)
- [Efinopegdutide: 72.7% liver fat drop vs 42.3% on semaglutide](https://pepvault.app/research/efinopegdutide-romero-gomez-2023)
- [Efinopegdutide: up to 7.2% more weight loss than placebo at 12 weeks](https://pepvault.app/research/efinopegdutide-di-prospero-2021)
- [All 3 studies](https://pepvault.app/research#efinopegdutide)

### Compared with

- [Pemvidutide vs Efinopegdutide](https://pepvault.app/peptides/compare/pemvidutide-vs-efinopegdutide)
- [Semaglutide vs Efinopegdutide](https://pepvault.app/peptides/compare/semaglutide-vs-efinopegdutide)
- [Survodutide vs Efinopegdutide](https://pepvault.app/peptides/compare/survodutide-vs-efinopegdutide)
- [Sermorelin vs Tesamorelin](https://pepvault.app/peptides/compare/sermorelin-vs-tesamorelin)
- [Ipamorelin vs Tesamorelin](https://pepvault.app/peptides/compare/ipamorelin-vs-tesamorelin)
- [HGH vs Tesamorelin](https://pepvault.app/peptides/compare/hgh-vs-tesamorelin)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### Related conditions

- [Peptides studied for obesity](https://pepvault.app/conditions/obesity)
- [Peptides studied for HIV lipodystrophy](https://pepvault.app/conditions/hiv-lipodystrophy)
- [Peptides studied for type 2 diabetes](https://pepvault.app/conditions/type-2-diabetes)
- [Peptides studied for obstructive sleep apnea](https://pepvault.app/conditions/sleep-apnea)

### By goal

- [Peptides for weight loss](https://pepvault.app/peptides/for/weight-loss)
- [Peptides for muscle growth](https://pepvault.app/peptides/for/muscle-growth)

### Terms on this page

- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Glucagon](https://pepvault.app/glossary/glucagon)
- [MASH](https://pepvault.app/glossary/mash)

<!--promo-->

PepVault for iPhone

## Track your own progress in PepVault

Doses, vials, weight and side effects in one log.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=conditions-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## By condition

- [Every condition](https://pepvault.app/conditions)
- [Peptides studied for obesity](https://pepvault.app/conditions/obesity)
- [Peptides studied for HIV lipodystrophy](https://pepvault.app/conditions/hiv-lipodystrophy)
- [Peptides studied for type 2 diabetes](https://pepvault.app/conditions/type-2-diabetes)
- [Peptides studied for obstructive sleep apnea](https://pepvault.app/conditions/sleep-apnea)

## The research

- [Studies, in plain English](https://pepvault.app/research)
- [The peptide reference library](https://pepvault.app/peptides)
- [Peptides by goal](https://pepvault.app/peptides/for)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
